Strategy for the Application of Therapy in Prostate Cancer
The rational application of integrated multidisciplinary therapy of prostate cancer (PC) requires an understanding of the determinants of cancer progression and response to therapy to successfully treat common adult cancers. In the successful examples of therapy application agents (chemotherapy, biologics) and other modalities (radiation, surgery) are applied on the basis of clinical biology during specific intervals in progression. Thus integrating the knowledge of clinical biology with an appreciation for the determinants is central to therapy development.
KeywordsProstate Cancer Gleason Score Serum Vascular Endothelial Growth Factor Prostate Cancer Progression Androgen Ablation
Unable to display preview. Download preview PDF.
- 4.Nelson WG, DeWeese TL, De Marzo AM, et al. (2002) Prostate cancer prevention, in Kantoff PW, Carroll PR, D’Amico AW (eds): Prostate Cancer: Principles and Practice. Philadelphia, PA, Lippincott Williams & Wilkins, pp. 67–72.Google Scholar
- 6.Whitmore Willet F (1990) Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17:689–697.Google Scholar
- 10.Kim J*, Sun P*, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lam YW, Lippman SM, McDonnell TJ, Lieberman R, Mobley JA, Logothetis CJ, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer (*co-first authors) (2005) Cancer Epidemiol Biomarkers Prev 14:1697–1702.PubMedCrossRefGoogle Scholar
- 11.Partin AW, Yoo J, Carter B, et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol I50:110–114.Google Scholar
- 19.Antwerp DJV, Martin SJ, Kafri T, et al. (1996) Suppression of the TNFα-induced apoptosis by NFκB. Nature 274:787–789.Google Scholar